Cargando…

Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients

BACKGROUND: Although PD-L1 expression is a crucial predictive biomarker for immunotherapy, it can be influenced by many factors. METHODS: A total of 248 Chinese patients with lung adenocarcinoma was retrospectively identified. Data for clinical features, gene alternations, signaling pathways and imm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Kang, Liu, Jun, Wu, Lin, Xiao, Yajie, Li, Jia, Du, Haijian, Zhao, Zhikun, Sun, Chao, Zhao, Yongtian, Yang, Jie, Wu, Dongfang, Zhao, Zhuxiang, Chen, Bolin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962080/ https://www.ncbi.nlm.nih.gov/pubmed/35346207 http://dx.doi.org/10.1186/s12935-022-02488-z

Ejemplares similares

Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes
por: Luo, Fan, et al.
Publicado: (2021)

Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections
por: Ye, Min, et al.
Publicado: (2020)

LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis
por: Wei, Shuquan, et al.
Publicado: (2019)

CD44, a marker of cancer stem cells, is positively correlated with PD-L1 expression and immune cells infiltration in lung adenocarcinoma
por: Zhang, Chenyue, et al.
Publicado: (2020)

A synthesized olean-28,13β-lactam targets YTHDF1-GLS1 axis to induce ROS-dependent metabolic crisis and cell death in pancreatic adenocarcinoma
por: Wu, Shijia, et al.
Publicado: (2022)

Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases
por: Liu, Drolaiz H. W., et al.
Publicado: (2023)

Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma
por: Boldrini, Laura, et al.
Publicado: (2017)

Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma
por: Ibrahiem, Afaf T., et al.
Publicado: (2023)

The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma
por: Lu, Jia, et al.
Publicado: (2022)

Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer
por: Ren, Qianqian, et al.
Publicado: (2020)

Expression of long non-coding RNA DLX6-AS1 in lung adenocarcinoma
por: Li, Juan, et al.
Publicado: (2015)

Programmed death-ligand 1 (PD-L1) expression in various tumor types
por: Grosso, Joseph, et al.
Publicado: (2013)

Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells
por: Jiang, Xiufeng, et al.
Publicado: (2019)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancer
por: Jiang, Cui, et al.
Publicado: (2019)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
por: Reddy, Vishwanatha R. A. P., et al.
Publicado: (2019)

Identification of APC Mutation as a Potential Predictor for Immunotherapy in Colorectal Cancer
por: Feng, Fen, et al.
Publicado: (2022)

Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer
por: Zhang, Chao, et al.
Publicado: (2021)

Exploring the Interplay between Metabolism and Tumor Microenvironment Based on Four Major Metabolism Pathways in Colon Adenocarcinoma
por: Qiao, Xiaofang, et al.
Publicado: (2022)

Association Between Intra-Tumoral Immune Response and Programmed Death Ligand 1 (PD-L1) in Gastric Cancer
por: Yan, Rong, et al.
Publicado: (2019)

The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
por: Chang, Boyang, et al.
Publicado: (2018)

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma
por: Botti, Gerardo, et al.
Publicado: (2017)

Programmed death ligand 1 (PD-L1) expression in parathyroid tumors
por: Pan, Boju, et al.
Publicado: (2019)

The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma
por: Wu, Shafei, et al.
Publicado: (2017)

Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer
por: Zhang, Jian, et al.
Publicado: (2019)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor
por: Brinch, Charlotte Margareta, et al.
Publicado: (2022)

The overall safety evaluation of programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1) treatment for lung cancer patients: An updated systematic review and meta-analysis
por: Shang, Heli, et al.
Publicado: (2019)

Adipocytes promote tumor progression and induce PD-L1 expression via TNF-α/IL-6 signaling
por: Li, Zhi, et al.
Publicado: (2020)

Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
por: Zhu, Jun, et al.
Publicado: (2017)

The interplay between ATF2 and NEAT1 contributes to lung adenocarcinoma progression
por: Liu, Jian, et al.
Publicado: (2020)

Therapeutic Effect of an Anti-Human Programmed Death-Ligand 1 (PD-L1) Nanobody on Polymicrobial Sepsis in Humanized Mice
por: Zhao, Zhen-zhen, et al.
Publicado: (2021)

HKDC1 promotes the tumorigenesis and glycolysis in lung adenocarcinoma via regulating AMPK/mTOR signaling pathway
por: Wang, Xinyu, et al.
Publicado: (2020)

Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer
por: Bari, Shahla, et al.
Publicado: (2019)

Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients
por: Liu, Shujun, et al.
Publicado: (2020)

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
por: Abaza, Abdelrahman, et al.
Publicado: (2023)

Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders
por: Zhao, Shangfeng, et al.
Publicado: (2014)

Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
por: Núñez Abad, Martín, et al.
Publicado: (2022)

The mechanism of lncRNAs in the crosstalk between epithelial-mesenchymal transition and tumor microenvironment for early colon adenocarcinoma based on molecular subtyping
por: Liang, Hanlin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gv17kidu4fsn86pkpfonlmk26e